GOSS
Gossamer Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.18
−0.17%Aug 21, 2026, 00:00 UTC
Gossamer Bio, Inc. signed a structured private placement on August 20, 2026, to raise up to $250 million through the sale of pre-funded warrants exercisable for convertible preferred stock and FDA Approval Warrants, with an initial closing expected on August 24, 2026.
Aug 13, 2026, 00:00 UTC
Gossamer Bio exchanged $181.1 million of its 2027 convertible notes for $65.2 million of new 2030 notes, reducing debt by $115.9 million.
Aug 13, 2026, 00:00 UTC
Gossamer Bio reported Q2 2026 revenue of $9.2 million and a net income of $16.9 million, with diluted EPS of -$0.08.
Source:Jul 27, 2026, 18:11 UTC
Gossamer Bio Inc. restructured its debt and secured full control of its lead drug candidate seralutinib.
Source:Jun 17, 2026, 12:00 UTC
Gossamer Bio, Inc. announced the final tender results of its exchange offer to exchange its 5.00% Convertible Senior Notes due 2025.
Source:Jun 11, 2026, 01:52 UTC
Harbour BioMed appointed Dr. Luisa Salter-Cid as Scientific Advisor.
Source:Jun 5, 2026, 00:00 UTC
Gossamer Bio entered into a Transaction Support Agreement with holders of approximately 75.2% of its outstanding Existing Convertible Notes to support an Exchange Offer and Consent Solicitation, which was signed on May 18, 2026 and automatically terminated on June 4, 2026 following early settlement of the Exchange Offer, and also amended the indenture governing the Existing Convertible Notes on June 4, 2026.
Jun 2, 2026, 12:00 UTC
Gossamer Bio, Inc. extended the early tender date for its exchange offer and consent solicitation regarding its existing convertible notes.
Jun 1, 2026, 09:28 UTC
A securities class action lawsuit was filed against Gossamer Bio, Inc. and an executive, alleging violations of federal securities laws related to the failure of its Phase 3 PROSERA study for seralutinib.
Source: